Catatonic signs in neuroleptic malignant syndrome

Comprehensive Psychiatry

Volumn 41, Issue 1, 2000, Pages 73-75

  Koch, Monika ^a,b   Chandragiri, Sanjay ^a,b   Rizvi, Syed ^a,b   Petrides, Georgios ^a,b   Francis, Andrew ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CATATONIA; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; MENTAL PATIENT; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PREDICTION; RATING SCALE; RETROSPECTIVE STUDY; SCHIZOPHRENIA;

EID: 0033978590     PISSN: 0010440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-440X(00)90135-4     Document Type: Article

References (21)

1. Fink M. Neuroleptic malignant syndrome and catatonia. One entity or two? Biol Psychiatry 1996;39:1-4.
2. Carroll BT, Taylor RE. The non dichotomy between lethal catatonia and neuroleptic malignant syndrome. J Clin Psychopharmacol 1997;17:235-238.
3. Northoff G, Wenke J, Pflug B. Increase of serum creatinine phosphokinase in catatonia: an investigation in 32 acute catatonic patients. Psychol Med 1996;26:547-553.
4. Carroll BT. Goforth HW. Serum iron in catatonia. Biol Psychiatry 1995;38:776-777.
5. Miyaoka H, Shishkura K, Otsubo T, Moramatsu D, Kamijima K. Diazepam-responsive neuroleptic malignant syndrome: a diagnostic subtype? Am J Psychiatry 1997;153:882 (letter).
6. Lew TY, Tollefson G. Chlorpromazine-induced neuroleptic syndrome and its response to lorazepam. Biol Psychiatry 1983;18:1441-1446.
7. Francis A, Chandragiri SS, Rizvi S, Koch M, Petrides G. Lorazepam treatment of neuroleptic malignant syndrome. Submitted.
8. Kontaxakis VP, Christodoulou GN, Markidis MP, Havaki-Kontaxaki BJ. Treatment of a mild form of neuroleptic malignant syndrome with oral diazepam. Acta Psychiatr Scand 1988;78:396-398.
9. White DAC. Catatonia and the neuroleptic malignant syndrome - a single entity? Br J Psychiatry 1992;161:558-560.
10. Fricchione G. Catatonia: a new indication for benzodiazepines? Biol Psychiatry 1989;26:761-765.
11. Francis A, Divadeenam K, Petrides G. Advances in the diagnosis and treatment of catatonia. Convuls Ther 1997;12:259-261.
12. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. Ed. 4. Washington, DC: American Psychiatric Press, 1994.
13. Caroff SN, Mann SC, Lazarus A. Neuroleptic malignant syndrome: diagnostic issues. Psychiatr Ann 1991;21:130-147.
14. Hynes AFM, Vickar EL. Case study: neuroleptic malignant syndrome without pyrexia. J Am Acad Child Adolesc Psychiatry 1996;35:959-961.
15. Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand 1996;93:129-136.
16. Castillo E, Rubin RT, Holsboer-Traschler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry 1989;146:324-328.
17. Rosebush PI, Mazurek MF. Serum iron and neuroleptic malignant syndrome. Lancet 1991;338:149-151.
18. Carroll BT, Boutros NN. Clinical electroencephalograms in patients with catatonic disorders. Clin Electroencephalogr 1995;26:60-64.
19. Lazarus A, Mann SC, Caroff SN (eds). The Neuroleptic Malignant Syndrome and Related Conditions. Washington, DC: American Psychiatric Press, 1989.
20. Northoff G, Demisch L, Wenke J, Pflug B. Plasma homovanillic acid concentrations in catatonia. Biol Psychiatry 1996;39:436-443.
21. Wetzel H, Heuser I, Benkert O. Stupor and affective state: alleviation of the psychomotor disturbances by lorazepam and recurrence of symptoms after Ro 15-1788. J Nerv Ment Dis 1987;175:240-242.